{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:23Z","timestamp":1707524723308},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"DOI":"10.7759\/cureus.28583","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T15:05:26Z","timestamp":1661871926000},"source":"Crossref","is-referenced-by-count":1,"title":["Methadone Prescribing for Pain Management in Pennsylvania per the Prescription Drug Monitoring Program, 2016\u20132020"],"prefix":"10.7759","author":[{"given":"Jenna  R","family":"Adalbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Hom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif M","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.2666","article-title":"Association of the use of a mandatory prescription drug monitoring program with prescribing practices for patients undergoing elective surgery","volume":"153","author":"Stucke RS","year":"2018","unstructured":"Stucke RS, Kelly JL, Mathis KA, Hill MV, Barth RJ Jr. Association of the use of a mandatory prescription drug monitoring program with prescribing practices for patients undergoing elective surgery. JAMA Surg. 2018, 153:1105-10. 10.1001\/jamasurg.2018.2666","journal-title":"JAMA Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.15.00614","article-title":"A prospective evaluation of opioid utilization after upper-extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines","volume":"98","author":"Kim N","year":"2016","unstructured":"Kim N, Matzon JL, Abboudi J, et al.. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am. 2016, 98:e89. 10.2106\/JBJS.15.00614","journal-title":"J Bone Joint Surg Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-19-00030","article-title":"Standardized, patient-specific, postoperative opioid prescribing after inpatient orthopaedic surgery","volume":"28","author":"Chen EY","year":"2020","unstructured":"Chen EY, Betancourt L, Li L, Trucks E, Marcantonio A, Tornetta P III. Standardized, patient-specific, postoperative opioid prescribing after inpatient orthopaedic surgery. J Am Acad Orthop Surg. 2020, 28:304-18. 10.5435\/JAAOS-D-19-00030","journal-title":"J Am Acad Orthop Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.07.659","article-title":"Opioid-prescribing guidelines for common surgical procedures: an expert panel consensus","volume":"227","author":"Overton HN","year":"2018","unstructured":"Overton HN, Hanna MN, Bruhn WE, Hutfless S, Bicket MC, Makary MA. Opioid-prescribing guidelines for common surgical procedures: an expert panel consensus. J Am Coll Surg. 2018, 227:411-8. 10.1016\/j.jamcollsurg.2018.07.659","journal-title":"J Am Coll Surg"},{"key":"ref5","unstructured":"About CDC\u2019s opioid prescribing guideline. Accessed. April 9, 2021: https:\/\/www.cdc.gov\/drugoverdose\/prescribing\/guideline.html."},{"key":"ref6","unstructured":"Prescription drug monitoring programs (PDMPs)|drug overdose|CDC injury center. Accessed. April 9, 2021: https:\/\/www.cdc.gov\/drugoverdose\/pdmp\/states.html."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.010","article-title":"Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing","volume":"199","author":"Strickler GK","year":"2019","unstructured":"Strickler GK, Zhang K, Halpin JF, Bohnert AS, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019, 199:1-9. 10.1016\/j.drugalcdep.2019.02.010","journal-title":"Drug Alcohol Depend"},{"key":"ref8","article-title":"Methadone treatment for pain states","volume":"71","author":"Toombs JD","year":"2005","unstructured":"Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician. 2005, 71:1353-8.","journal-title":"Am Fam Physician"},{"key":"ref9","article-title":"Methadone as an analgesic: a review of the risks and benefits","volume":"103","author":"Terpening CM","year":"2007","unstructured":"Terpening CM, Johnson WM. Methadone as an analgesic: a review of the risks and benefits. W V Med J. 2007, 103:14-8.","journal-title":"W V Med J"},{"key":"ref10","unstructured":"Most states list deadly methadone as a \"preferred drug\". (2015). Accessed. August 15, 2021: https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/blogs\/stateline\/2015\/4\/23\/most-states-list-deadly-methadone-as-a-p...."},{"key":"ref11","unstructured":"Questions and answers (Q&A). Accessed. April 10, 2021: https:\/\/www.health.pa.gov\/topics\/programs\/PDMP\/Pages\/QA.aspx."},{"key":"ref12","unstructured":"2014 Act 191-PA general assembly. (2014). Accessed. April 10, 2021: https:\/\/www.legis.state.pa.us\/cfdocs\/legis\/li\/uconsCheck.cfm?yr=2014&sessInd=0&act=191."},{"key":"ref13","unstructured":"Changes to Pennsylvania drug monitoring program as of January 1, 2017. compliance for prescribing physicians. (2017). Accessed:  April 8, 2021: https:\/\/www.mcneeslaw.com\/changes-pennsylvania-drug-monitoring-program-january-1-2017-compliance-prescribing-physicians\/."},{"key":"ref14","unstructured":"PA counties-overview. (2012). Accessed. October 26, 2021: https:\/\/www.arcgis.com\/home\/item.html?id=04e3f70b4b7f401faafd431da9355ab4."},{"key":"ref15","unstructured":"U.S. Census Bureau QuickFacts. Pennsylvania. (2021). Accessed: October 26, 2021: https:\/\/www.census.gov\/quickfacts\/PA."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2018.01.034","article-title":"Trends in medical use of opioids in the U.S., 2006-2016","volume":"54","author":"Piper BJ","year":"2018","unstructured":"Piper BJ, Shah DT, Simoyan OM, McCall KL, Nichols SD. Trends in medical use of opioids in the U.S., 2006-2016. Am J Prev Med. 2018, 54:652-60. 10.1016\/j.amepre.2018.01.034","journal-title":"Am J Prev Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211028262","article-title":"Pronounced regional disparities in United States methadone distribution","volume":"56","author":"Furst JA","year":"2022","unstructured":"Furst JA, Mynarski NJ, McCall KL, Piper BJ. Pronounced regional disparities in United States methadone distribution. Ann Pharmacother. 2022, 56:271-9. 10.1177\/10600280211028262","journal-title":"Ann Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths-United States, 2002-2014","volume":"65","author":"Jones CM","year":"2016","unstructured":"Jones CM, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths-United States, 2002-2014. MMWR Morb Mortal Wkly Rep. 2016, 65:667-71. 10.15585\/mmwr.mm6526a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6612a2","article-title":"Methadone prescribing and overdose and the association with Medicaid preferred drug list policies-United States, 2007-2014","volume":"66","author":"Faul M","year":"2017","unstructured":"Faul M, Bohm M, Alexander C. Methadone prescribing and overdose and the association with Medicaid preferred drug list policies-United States, 2007-2014. MMWR Morb Mortal Wkly Rep. 2017, 66:320-3. 10.15585\/mmwr.mm6612a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.9289","article-title":"Methadone overdose deaths rise with increased prescribing for pain","volume":"308","author":"Kuehn BM","year":"2012","unstructured":"Kuehn BM. Methadone overdose deaths rise with increased prescribing for pain. JAMA. 2012, 308:749-50. 10.1001\/jama.2012.9289","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2012.0126","article-title":"Rethinking methadone for the management of chronic pain","volume":"8","author":"Reisfield GM","year":"2012","unstructured":"Reisfield GM, Sloan PA. Rethinking methadone for the management of chronic pain. J Opioid Manag. 2012, 8:271-2. 10.5055\/jom.2012.0126","journal-title":"J Opioid Manag"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: a pharmacotherapeutic review","volume":"34","author":"Kreutzwiser D","year":"2020","unstructured":"Kreutzwiser D, Tawfic QA. Methadone for pain management: a pharmacotherapeutic review. CNS Drugs. 2020, 34:827-39. 10.1007\/s40263-020-00743-3","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.04.004","article-title":"Methadone in pain management: a systematic review","volume":"22","author":"Hanna V","year":"2021","unstructured":"Hanna V, Senderovich H. Methadone in pain management: a systematic review. J Pain. 2021, 22:233-45. 10.1016\/j.jpain.2020.04.004","journal-title":"J Pain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721002051","article-title":"Reduced mortality in patients with extended duration of methadone maintenance treatment: a five-year retrospective nationwide study","author":"Huang CL","year":"2021","unstructured":"Huang CL, Tsai IJ, Lin WC, Lin CL, Ho IK, Wang RY, Lee CW. Reduced mortality in patients with extended duration of methadone maintenance treatment: a five-year retrospective nationwide study. Psychol Med. 2021, 1-9. 10.1017\/S0033291721002051","journal-title":"Psychol Med"},{"key":"ref25","unstructured":"Certification of opioid treatment programs (OTPs)|SAMHSA. (2021). Accessed. August 17, 2021: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/become-accredited-opioid-treatment-program."},{"key":"ref26","article-title":"Vital signs: risk for overdose from methadone used for pain relief-United States, 1999-2010","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief-United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012, 61:493-7.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref27","unstructured":"Prescription drug monitoring programs (PDMPs). (2018). Accessed. August 17, 2021: https:\/\/www.asam.org\/advocacy\/public-policy-statements\/details\/public-policy-statements\/2021\/08\/09\/prescription-drug-...."},{"key":"ref28","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob R","year":"2018","unstructured":"Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine therapy for opioid use disorder. Am Fam Physician. 2018, 97:313-20.","journal-title":"Am Fam Physician"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/2197-1714-1-9","article-title":"Prescription drug monitoring and drug overdose mortality","volume":"1","author":"Li G","year":"2014","unstructured":"Li G, Brady JE, Lang BH, Giglio J, Wunsch H, DiMaggio C. Prescription drug monitoring and drug overdose mortality. Inj Epidemiol. 2014, 1:9. 10.1186\/2197-1714-1-9","journal-title":"Inj Epidemiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4003","article-title":"Characteristics of state prescription drug monitoring programs: a state-by-state survey","volume":"25","author":"Manasco AT","year":"2016","unstructured":"Manasco AT, Griggs C, Leeds R, Langlois BK, Breaud AH, Mitchell PM, Weiner SG. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Pharmacoepidemiol Drug Saf. 2016, 25:847-51. 10.1002\/pds.4003","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105230-methadone-prescribing-for-pain-management-in-pennsylvania-per-the-prescription-drug-monitoring-program-2016-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:57Z","timestamp":1707508137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105230-methadone-prescribing-for-pain-management-in-pennsylvania-per-the-prescription-drug-monitoring-program-2016-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.28583","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}